These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

65 related items for PubMed ID: 2937860

  • 21. [Clinical significance of pregnancy-specific beta 1-glycoprotein analysis in endocrine tests of the gonadal and placental system].
    Mochizuki M.
    Nihon Rinsho; 1989 Dec; 48 Suppl():1274-8. PubMed ID: 2560074
    [No Abstract] [Full Text] [Related]

  • 22. Placental protein 5 (PP5): biological and clinical studies.
    Salem HT, Chard T.
    Placenta Suppl; 1982 Dec; 4():103-14. PubMed ID: 6100760
    [No Abstract] [Full Text] [Related]

  • 23. A study on the serum pregnancy zone protein levels in pregnant women and patients with gynecological tumors.
    Teng H, Zhang WY, Zhu FQ.
    Chin Med J (Engl); 1994 Dec; 107(12):910-4. PubMed ID: 7882729
    [Abstract] [Full Text] [Related]

  • 24. [Changes in blood rheological properties in gynecologic tumors in the postoperative period].
    Karabanov GN, Nikov NP.
    Vopr Onkol; 1983 Dec; 29(7):85-8. PubMed ID: 6880138
    [Abstract] [Full Text] [Related]

  • 25. Serum and tissue measurements of CA72-4 in ovarian cancer patients.
    Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, Asano G.
    Gynecol Oncol; 1993 Feb; 48(2):148-54. PubMed ID: 8381375
    [Abstract] [Full Text] [Related]

  • 26. [Blood group frequencies in obstetric and gynecologic diseases].
    Balika IuD, Trepakov EA.
    Akush Ginekol (Mosk); 1977 Dec; (12):45-7. PubMed ID: 564616
    [No Abstract] [Full Text] [Related]

  • 27. [The biochemical aspects of trophoblastic disease].
    Massart C, Le Pogamp C.
    Arch Anat Cytol Pathol; 1983 Dec; 31(2):115-6. PubMed ID: 6309102
    [No Abstract] [Full Text] [Related]

  • 28. [Trophoblastic beta 1-glycoprotein in the blood in trophoblastic tumors].
    Sokolov AV, Zhordaniia KI, Ledian KM.
    Med Radiol (Mosk); 1983 Aug; 28(8):25-31. PubMed ID: 6310307
    [Abstract] [Full Text] [Related]

  • 29. Binding of specific peroxidase-labeled antibody to placental-type phosphatase on tumor-derived membrane fragments.
    Taylor DD, Homesley HD, Doellgast GJ.
    Cancer Res; 1980 Nov; 40(11):4064-9. PubMed ID: 7008934
    [Abstract] [Full Text] [Related]

  • 30. New placental proteins in placental dysfunction.
    Lee JN, Chard T.
    Contrib Gynecol Obstet; 1982 Nov; 9():157-69. PubMed ID: 6183052
    [No Abstract] [Full Text] [Related]

  • 31. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
    Kawai M, Yamashita H, Hayashi T, Kamiya N, Kakihara M, Arii Y.
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
    [Abstract] [Full Text] [Related]

  • 32. [Variations in the level of immunosuppressive acidic protein in patients with gynecologic tumors and pregnant women].
    Sawada M, Okudaira Y, Matsui Y, Miyoshi Y, Takayama K, Shimizu Y, Miura S.
    Gan To Kagaku Ryoho; 1983 Aug; 10(8):1823-30. PubMed ID: 6882005
    [Abstract] [Full Text] [Related]

  • 33. Serum levels of the progesterone induced blocking factor do not precipitously rise in women with gynecologic cancer in contrast to women exposed to progesterone.
    Check JH, Sarumi M, DiAntonio A, Hunter K, Simpkins G, Duroseau M.
    Clin Exp Obstet Gynecol; 2015 Aug; 42(5):563-7. PubMed ID: 26524797
    [Abstract] [Full Text] [Related]

  • 34. [Clinical significance of CA 19-9 as a tumor marker for gynecologic malignancies].
    Inoue M, Saitoh J, Abe Y, Inoue Y, Ueda G, Tanizawa O, Gamoh Y, Dan A, Satoh T.
    Nihon Sanka Fujinka Gakkai Zasshi; 1985 Nov; 37(11):2411-4. PubMed ID: 3865972
    [No Abstract] [Full Text] [Related]

  • 35. Carcinoma of the ovary and serum lactic dehydrogenase levels.
    Awais GM.
    Surg Gynecol Obstet; 1978 Jun; 146(6):893-5. PubMed ID: 653563
    [Abstract] [Full Text] [Related]

  • 36. [Studies on clinical usefulness of new tumor markers of ovarian cancer, CA54/61 and CA602--III. Measurement of serum samples from patients with various benign or malignant diseases].
    Nozawa S, Udagawa Y, Sasaki H, Ito K, Akiya K, Terashima Y, Takamizawa H, Ohkura H, Fujimoto S, Hashimoto M.
    Gan To Kagaku Ryoho; 1994 May; 21(6):823-32. PubMed ID: 8185340
    [Abstract] [Full Text] [Related]

  • 37. Pregnancy coexisting with serous papillary adenocarcinoma involving both uterus and ovary.
    Fine BA, Baker TR, Hempling RE, Intengan M.
    Gynecol Oncol; 1994 Jun; 53(3):369-72. PubMed ID: 8206413
    [Abstract] [Full Text] [Related]

  • 38. Clinical value of sialyl Tn antigen in patients with gynecologic tumors.
    Inoue M, Ogawa H, Nakanishi K, Tanizawa O, Karino K, Endo J.
    Obstet Gynecol; 1990 Jun; 75(6):1032-6. PubMed ID: 2342728
    [Abstract] [Full Text] [Related]

  • 39. [Study on the pretherapeutic differential diagnosis of adnexal tumors].
    Kunz J, Kunz B.
    Praxis (Bern 1994); 1995 Nov 14; 84(46):1342-8. PubMed ID: 7491464
    [Abstract] [Full Text] [Related]

  • 40. Carcinoembryonic antigen in gynecologic patients. II. Immunohistological expression.
    Fenoglio CM, Crum CP, Pascal RR, Richart RM.
    Diagn Gynecol Obstet; 1981 Nov 14; 3(4):291-9. PubMed ID: 7338157
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 4.